Cadrenal Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Cadrenal Therapeutics, Inc. filed a Form 8-K dated March 11, 2024, reporting entry into a material definitive agreement. The company is an emerging growth company whose common stock trades on Nasdaq under the symbol CVKD.
Material financing arrangement
On March 11, 2024, the company entered into an At-the-Market Offering Agreement with H.C. Wainwright & Co., LLC as sales agent. The agreement permits the company to offer and sell up to $5,143,730 of common stock from time to time through an ATM program.
- Sales are subject to the effectiveness of a related Form S-3 registration statement filed with the SEC on March 11, 2024.
- The company is not obligated to sell any shares and may suspend or terminate sales.
- The company will determine the timing, amount, daily limits and minimum price for sales.
- Wainwright will receive compensation equal to 3.0% of the gross sales price of shares sold through the program.
- The agreement includes customary representations, warranties, indemnification provisions and termination rights.
Financial metrics and liquidity
The filing does not provide revenue, profit, cash flow, operating margin, debt, cash balance or other current-period financial metrics. It also does not state how much stock, if any, had been sold under the ATM program as of the filing date.
Changes versus the prior comparable period
The filing text does not provide a prior-period financial comparison. The material change disclosed is the establishment of a potential equity financing facility for up to $5,143,730.
Guidance, outlook, risks and unusual items
- The registration statement may not become effective, and the company provides no assurance regarding its effectiveness or continued effectiveness.
- Any equity sales would provide potential funding but may dilute existing stockholders.
- Shares may be sold at prevailing market prices, subject to company-established parameters.
- The agreement may be terminated by either party under specified circumstances, including a material adverse change affecting the company.
- The filing contains no financial guidance or operating outlook.
Investor verification checklist
- Verify whether the Form S-3 registration statement became effective.
- Check subsequent filings for shares sold, gross proceeds, net proceeds and remaining ATM capacity.
- Assess the potential dilution from any shares issued under the program.
- Review the company’s latest balance sheet and cash runway to determine the financing need.
- Review Exhibit 1.1 for the complete terms, termination provisions and indemnification obligations.